The QualityStocks Daily Monday, February 13th, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(VLON) $0.8800 +90.27%

QualityStocks(CJJD) $7.1000 +43.43%

The Stock Dork(OCUL) $5.2300 +35.14%

The QualityStocks Daily Stock List

China Jo-Jo Drug Stores (CJJD)

QualityStocks, MarketBeat, SmallCapVoice, BUYINS.NET, StocksEarning, StockOodles, StreetInsider, The Street, StockRockandRoll, The Online Investor, ResearchOTC, PennyStockLocks.com, Street Insider, Wall Street Resources, The Weekly Options Trader, PennyTrader Publisher, Penny Stock Rumble, MarketClub Analysis, TradersPro, INO.com Market Report and StockMarketWatch reported earlier on China Jo-Jo Drug Stores (CJJD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

China Jo-Jo Drugstores Inc. (NASDAQ: CJJD) (FRA: 04CN) is engaged in the distribution and retail of pharmaceutical products as well as other healthcare products in China.

The firm has its headquarters in Hangzhou, the People’s Republic of China and was incorporated in 2006, on December 19th by Li Qi and Lei Liu. It operates in the consumer staples sector, under the retail and wholesale industry. The firm serves consumers in China.

The enterprise operates through the following segments: herb farming, drug wholesale, online pharmacy and retail drugstores. The farming segment grows various herbs which are sold to other drug vendors while the wholesale segment is engaged in the supply of the enterprise’s drug stores with medications, sundry items and medical devices. Additionally, the drugstores segment is involved in the sale of medical devices, family and personal care products, traditional Chinese medicine, nutritional supplements, over-the-counter and prescription medications and convenience products which include promotional, seasonal and consumable items. The online pharmacy is involved in the sale of nutritional supplements and other products via 3rd party platforms like Amazon.com and JD.com as well as its own platform, called dada360.com.

As of March 31, 2020, the company had 10 pharmacies and over 115 retail pharmacies under the Jiuzhou Grand Pharmacy name. The firm received the CHEO Award from the China Health Ecology Organization in September 2020, which is a health industry conference that has great influence and high standards. This award helps boost confidence in the firm, which is actively striving to promote their smart medicine diagnosis model.

China Jo-Jo Drug Stores (CJJD), closed Monday's trading session at $7.1, up 43.4343%, on 5,262,983 volume. The average volume for the last 3 months is 175.127M and the stock's 52-week low/high is $1.43/$7.9099.

ContextLogic Inc. (WISH)

Schaeffer's, InvestorPlace, MarketBeat, StocksEarning, MarketClub Analysis, Trades Of The Day, The Street, Daily Trade Alert, StockEarnings, Rick Saddler, QualityStocks, Marketbeat.com and Investing Daily reported earlier on ContextLogic Inc. (WISH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ContextLogic Inc. (NASDAQ: WISH) (FRA: 5ZZ) is a mobile e-commerce firm that is focused on the provision of e-commerce services.

The firm has its headquarters in San Francisco, California and was incorporated in June 2010 by Danny Zhang and Peter Szulczewski. It operates as part of the advertising, public relations and related services industry. The firm has eight companies in its corporate profile and serves consumers in South America, North America, Europe and internationally.

The company allows users to find products easily and personalize their shopping experiences. This is in addition to helping merchants reach consumers. It generates most of its revenue from Europe.

The enterprise offers a discovery-based platform which uses user preferences to connect users to products. Its personalized product feed allows users to find new products to buy by browsing and scrolling through its mobile app. The enterprise integrates user-generated content, which includes reviews, videos and photos. It also offers an advertising tool for merchants known as ProductBoost, which enables them to promote their products on the platform. This is in addition to offering other services to merchants, which include business operations support, promotional and logistics capabilities, data intelligence, user-generated content creation and demand engagement and generation. Furthermore, it helps merchants with user support, payment processing and international compliance.

The company recently entered into a partnership with Correos, which is a state-owned Spanish carrier. This move not only aligns with the company’s aim to work with more local suppliers on a global scale but will also help extend their consumer reach, which may encourage more investments into the firm and boost its growth.

ContextLogic Inc. (WISH), closed Monday's trading session at $0.8787, up 37.3398%, on 175,126,725 volume. The average volume for the last 3 months is 4.812M and the stock's 52-week low/high is $0.4353/$2.67.

NGL Energy Partners (NGL)

MarketBeat, Zacks, TradersPro, Marketbeat.com, Investing Daily, StreetInsider, Barchart, InvestorPlace, Investors Alley, The Street, The Online Investor, Market Intelligence Center Alert, StockMarketWatch, Schaeffer's, Daily Trade Alert, MarketClub Analysis, Trades Of The Day, Super Stock Picker, Trading Concepts, QualityStocks, AllPennyStocks, The Weekly Options Trader, Top Pros' Top Picks, InvestmentHouse, Investing Futures, Insider Wealth Alert and Uncommon Wisdom reported earlier on NGL Energy Partners (NGL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NGL Energy Partners LP (NYSE: NGL) is focused on refined products, liquids, water solutions and crude oil logistics businesses.

The company operates in the United States and is based in Tulsa, Oklahoma. It was incorporated in 1940 and has NGL Energy Holdings LLC serving as its general partner. The company operates through the Corporate and other, Refined products and renewables, Liquids, Water solutions and Crude oil logistics segments.

The Corporate and other segment comprises of corporate expenses that haven’t been allocated to reportable segments while the Refined products and renewables segment carries out biodiesel, ethanol, diesel and gasoline marketing operations. On the other hand, its Liquid segment is engaged in the supply of natural gas liquids to petrochemical plants, refiners, wholesalers and retailers while its Water solutions segment offers services for the disposal of solids like drilling fluids and tank bottoms as well as the disposal and treatment of wastewater generated from natural gas and crude oil production. Lastly, the Crude oil segment buys crude oil from producers and takes it to refineries or resales it at leased and owned pipeline injection stations, rail facilities, barge loading facilities, storage terminals and other trade hubs.

The company sells distillates and propane and also supplies natural gas liquids to petrochemical plants, refiners, wholesalers and retailers.

The enterprise recently completed the Poker Lake pipeline and its Water Solutions segment is already receiving disposable volumes from its Poker Lake Development. This move will facilitate future growth for the development, which is bound to increase the firm’s earnings.

NGL Energy Partners (NGL), closed Monday's trading session at $2.68, up 28.8462%, on 4,867,740 volume. The average volume for the last 3 months is 94.822M and the stock's 52-week low/high is $1.00/$2.74.

TOP Ships, Inc. (TOPS)

Profitable Trader Authority, BUYINS.NET, QualityStocks, StockMarketWatch, Promotion Stock Secrets, RedChip, MarketBeat, PennyStockScholar, OTCPicks, StreetInsider, OTCtipReporter, Jason Bond, MarketClub Analysis, PennyStocks24, TraderPower, The Online Investor, Greenbackers, Wall Street Resources, AllPennyStocks, Wall Street Mover, Dynamic Wealth Report, INO Market Report, The Street, AimHighProfits, StockOodles, Stock Beast, Penny Stock Prodigy, SmarTrend Newsletters, SmallCapInvestor.com, Small Cap Firm, TopPennyStockMovers and The Stock Dork reported earlier on TOP Ships, Inc. (TOPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TOP Ships, Inc. is a global owner and operator of modern, fuel efficient “ECO” tanker vessels. At present, it is focusing on the transportation of crude oil and petroleum products. The Company’s strategy is to grow its fleet by way of acquisitions of newbuilding, resale or second-hand vessels of premier quality ECO design. Incorporated in the Republic of The Marshall Islands, TOP Ships is based in Marousi, Greece. The Company also has a London and Monaco office.

TOP Ships’ Management Team consists of executives with wide-ranging experience in managing and operating large and diversified fleets of vessels, and with strong ties to several national, regional and international oil companies, charterers and traders. The Company’s Management Team has 94 years of combined shipping experience.

TOP Ships has a high specification ECO design fleet. All vessels are fitted with Ballast Water Treatment Systems and part of the fleet is fitted with Scrubbers. On delivery of its last new building vessel, TOP Ships 14 vessel fleet average age will be 2,0 years - one of the youngest Tanker fleets in the world.

TOP Ships previously took delivery of three ECO MR Product Tankers (two of which in the 50 percent-50 percent joint venture (JV) with Gunvor S.A.). In 2019, the Company took delivery of two ECO MR Product Tankers and two ECO Suezmax Tankers. All vessels are scrubber fitted except for one MR Product Tanker that is Scrubber ready.

TOP Ships, Inc. (TOPS), closed Monday's trading session at $1.65, up 25.9542%, on 94,822,108 volume. The average volume for the last 3 months is 1,004 and the stock's 52-week low/high is $0.105/$11.60.

Prime Mining (PRMNF)

We reported earlier on Prime Mining (PRMNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Prime Mining Corp. (OTCQX: PRMNF) (CVE: PRYM) (FRA: O4V3) is a company focused on acquiring, exploring for and developing mineral resources properties in Mexico, primarily targeting high-value and specialty metals.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1981, on May 14th. Prior to its name change in August 2019, the firm was known as ePower Metals Inc. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers in Canada.

The company primarily explores for gold and silver deposits. It hopes to deliver shareholder value through strong leadership and technical excellence. The company’s subsidiaries include ePower Metals SA de CV, Minera Amari SA de CV and Argus Metals (BGI) Inc.

The enterprise is focused on unlocking the full potential of its wholly owned high-grade Los Reyes low sulphidation epithermal gold-silver project. This project, which comprises of 37 contiguous concessions that cover an area of 6,273 hectares, is located in the Guadalupe de los Reyes mining district in the western foothills of the Sierra Madre Occidental mountain range, Sinaloa State, Mexico. The Los Reyes Project hosts gold resources of roughly 633 thousand ounces (kozs) measured and indicated, and over 179 kozs inferred. It also hosts silver resources of about 16,604 kozs measured and indicated, and more than 6,831 kozs inferred.

The firm, which recently announced its latest financial results, appointed a new Executive VP with decades of experience in mining. This move may positively influence investments and revenues into the firm while also helping create shareholder value.

Prime Mining (PRMNF), closed Monday's trading session at $1.46, up 0.343643%, on 1,004 volume. The average volume for the last 3 months is 703,282 and the stock's 52-week low/high is $0.80/$3.29.

Electrovaya (EFLVF)

Top Pros' Top Picks and MarketBeat reported earlier on Electrovaya (EFLVF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Electrovaya Inc. (OTCQB: EFLVF) (TSE: EFL) (FRA: 4EV) is lithium-ion battery technology and manufacturing firm that is focused on the design, development and manufacture of Li-ion advanced battery systems for clean electric transportation, energy storage and other specialized applications, in North America.

The firm has its headquarters in Mississauga, Canada and was incorporated in September 1996 by James K. Jacobs and Sankar Das Gupta. Prior to its name change in March 2002, the firm was known as Electrofuel Inc. It operates as part of the electrical equipment and parts industry, under the industrials sector. The firm serves consumers across the globe.

The technology-focused company is leading the global transformation to green energy. With its battery technology being used at some of the leading corporations globally, it is partnering in the global initiative to reduce carbon emissions. The company has an extensive IP portfolio, with production facilities in Canada. It generates most of its revenue from the sale of batteries and battery systems. Geographically it earns the majority of its revenue from the U.S.

The enterprise provides Li-ion batteries and systems for materials handling electric vehicles (MHEVs), including forklifts and automated guided vehicles (AGVs); and electromotive power products for electric trucks, electric buses, and other transportation applications. It also offers industrial products for energy storage; battery chargers to charge batteries; and complex power solutions like competencies in building systems for third parties.

The company recently announced its latest financial results, which show increases in its revenues. It remains focused on reducing carbon emissions and generating shareholder value.

Electrovaya (EFLVF), closed Monday's trading session at $0.971, up 3.5181%, on 703,282 volume. The average volume for the last 3 months is 27,000 and the stock's 52-week low/high is $0.4049/$1.01.

Lotus Resources (LTSRF)

MarketBeat reported earlier on Lotus Resources (LTSRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lotus Resources Ltd (OTCQB: LTSRF) (ASX: LOT) is a mineral exploration firm that is focused on exploring for, developing and evaluating mineral properties in Africa and Australia.

The firm has its headquarters in Perth, Australia and was incorporated in June 2006. Prior to its name change in August 2019, the firm was known as Hylea Metals Ltd. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm primarily serves consumers in Australia.

The company operates in two business segments; the exploration, evaluation and development of Uranium assets in Africa; and the exploration and evaluation of Other Minerals in Australia. It operates through its subsidiaries, which include Providence Metals Pty Ltd, Westview Resources Pty Ltd, Lily Resources Pty Ltd and Lotus (Africa) Ltd.

The enterprise’s project portfolio is comprised of the Kayelekera uranium project, the Hylea cobalt project and the Livingstonia project. It holds an 85% interest in the Kayelekera project, a sandstone-hosted uranium deposit associated with the Permian Karoo sediments. This project is situated in the northern region of Malawi, roughly 650km north of Lilongwe, the country’s capital. The Hylea cobalt project is located over units of the western side of the Lachlan Orogen; and the Livingstonia project located in northern Malawi.

The firm, which recently provided an update on its operations, is focused on building a long-term strategy that will enable it to become a multi-decade supplier in the industry. This will, in turn, bring in additional revenues into the firm.

Lotus Resources (LTSRF), closed Monday's trading session at $0.155725, off by 3.8735%, on 27,000 volume. The average volume for the last 3 months is 371,118 and the stock's 52-week low/high is $0.1059/$0.328.

Dolly Varden Silver (DOLLF)

We reported earlier on Dolly Varden Silver (DOLLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Dolly Varden Silver Corp. (OTCQX: DOLLF) (CVE: DV) (LON: 0USB) (DRA: DVQ1) is a mineral exploration firm that is focused on acquiring, exploring for and developing mineral properties in Canada.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2011, on March 4th. It operates as part of the silver industry, under the basic materials sector. The firm serves consumers in Canada.

The company explores for gold, silver, lead, zinc and copper deposits. Its portfolio is comprised of the Kitsault Valley project and the Big Bulk property.

The enterprise holds 100% interests in the Kitsault Valley project, which comprises the Dolly Varden property and the Homestake Ridge property, covering an area of 163 km2 located in Golden Triangle of British Columbia, Canada. The project hosts high-grade silver and gold resources along with the past producing Dolly Varden and Torbrit silver mines. It is considered to be prospective for hosting further precious metal deposits, being on the same structural and stratigraphic belts that host numerous other, on-trend, high-grade deposits, such as Eskay Creek and Brucejack. The Kitsault Valley Project also contains the Big Bulk property, which is prospective for porphyry and skarn style copper and gold mineralization, similar to other such deposits in the region (Red Mountain, KSM, Red Chris). This is in addition to holding 100% interest in the Big Bulk property located in Canada.

The firm is focused on pursuing other business opportunities while generating value for its shareholders, which will positively influence its overall growth.

Dolly Varden Silver (DOLLF), closed Monday's trading session at $0.715, off by 5.9458%, on 371,118 volume. The average volume for the last 3 months is 3,683 and the stock's 52-week low/high is $0.261/$0.8644.

Rock Tech Lithium (RCKTF)

Streetwise Reports and MarketBeat reported earlier on Rock Tech Lithium (RCKTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rock Tech Lithium Inc. (OTCQX: RCKTF) (CVE: RCK) (FRA: RJIB) is a lithium chemical technology firm that is focused on exploring for and developing lithium and rare metal properties in Canada.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1996, on June 14th. Prior to its name change in April 2010, the firm was known as Rock Tech Resources Inc. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers around the globe.

The company, whose goal is to become the first closed-loop lithium firm globally, is focused on producing lithium chemicals for electric vehicle batteries. It sources raw material from its own mineral project in Canada. The company primarily operates through the Canada and Germany geographical segments.

The enterprise holds a 100% interest in the Georgia Lake lithium project, which consists of 277 claim units and 41 mining leases, located in the Thunder Bay Mining District of Ontario. The project is located in an area underlain by metasediments and metavolcanics of Archean age. The enterprise is also focused on building European and North American lithium hydroxide conversion capacity that seeks to convert hard rock lithium feedstock into a lithium chemical used in the battery industry. It seeks to supply high-quality lithium hydroxide to the automotive industry globally, with a focus on Germany.

The firm is focused on creating an energy-efficient future, which will help to better meet its clients’ needs while also encouraging more investments into the firm.

Rock Tech Lithium (RCKTF), closed Monday's trading session at $2.1755, off by 7.4255%, on 3,683 volume. The average volume for the last 3 months is 16,500 and the stock's 52-week low/high is $1.4827/$5.39.

Electronic Servitor Publication Network Inc. (XESP)

We reported earlier on Electronic Servitor Publication Network Inc. (XESP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Electronic Servitor Publication Network (OTCQB: XESP), a managed digital engagement solutions company, announced the appointment of a seasoned veteran as its new president and CEO. Peter Hager, who has an impressive three-decade track record of cross-industry experience, will be taking over leadership of the company. Hager comes from Pointward Inc., a medtech customer agency company that he founded, which provided business solutions to drive market entry, commercialization, and growth for Fortune 500 healthcare brands and medtech startups looking to improve the quality of healthcare. Prior to that, Hager founded and served as a director for several technology, professional services and medtech organizations, including PhiTech Management, iSight Therapeutics, TeamNet Systems and Bluestem Technologies. “Peter is committed to giving back to the community and serves organizations that support youth, both locally and globally,” the company stated in the announcement. “He serves or has served on the boards of the Sanneh Foundation, the All 4 Kids Foundation, Custom One Charities and The Minnesota Adoption Resource Network. Through his work with these organizations, Peter is dedicated to making a positive impact in the lives of young people and contributing to a better future for all.”

To view the full press release, visit https://ibn.fm/Jklg1

About Electronic Servitor Publication Network Inc.

Electronic Servitor Publication Network provides managed digital engagement solutions to established and developing organizations that seek to enhance their profitability through effective and efficient online content management. XESP addresses market deficiencies by providing clients access to the benefits of their digital engagement engine and their proven processes. The all-encompassing service offering provides clients with overarching digital management that ensures all aspects of their content is continuously monitored, analyzed, managed, and enhanced, no matter what programs and processes they already have in place. For more information about the company, please visit www.XESPN.com.

Electronic Servitor Publication Network Inc. (XESP), closed Monday's trading session at $0.066, even for the day. The average volume for the last 3 months is 708,689 and the stock's 52-week low/high is $0.03/$0.4899.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The past two decades have been characterized by numerous drug reform initiatives that have resulted in controlled substances such as cannabis and psychedelics being recognized for their medical potential. While there has been a decent amount of research into cannabis thanks to loosening reforms across the country, psychedelic research is still in its infancy.

Despite this limited research, hallucinogens have exhibited immense potential as treatments against a variety of mental health conditions in initial studies. The result has been a surge of research into the potential benefits and risks of using psychedelics to treat mental disorders such as depression, post-traumatic stress disorder and anxiety.

Results from most of these new studies have been quite promising and have propped up hallucinogenic drugs as a potential alternative medication for pharmaceutical psychiatric drugs.

Although we still don’t fully understand how psychedelics are able to deliver profound mental health benefits in relatively limited doses, research suggests that they act on neurotransmitters in the body to deliver the benefits. This makes it possible for psychedelics to alleviate the symptoms of conditions such as PTSD and anxiety even when, or especially when, traditional means of treatment have failed to have a positive impact.

One of the primary benefits of using psychedelics to address mental ailments such as anxiety and PTSD is that they act relatively quickly. While traditional therapies can take weeks to cause a noticeable reduction in symptoms, psychedelics, such as ketamine, MDMA and ayahuasca, can provide relatively immediate benefits to the patient.

A Weill Cornell Medicine study revealed that LSD and psilocybin, the hallucinogenic compound found in magic mushrooms, aid in the activation of serotonin receptors in the brain and reduce the energy needed to move from one mental state to another. This in turn makes it much easier for patients to shift from potentially harmful mindsets to healthier ones; it also improves mood.

Furthermore, going into a guided psychedelic experience makes patients more suggestible and makes it easier for therapists and medical companions to provide useful suggestions and guidance.

Another survey-based study found that psychedelics delivered significant benefits against depression and anxiety by reducing stress levels and the number of depressive episodes in patients. Repeated exposure to hallucinogenic drugs also helped to reduce mental discomfort in patients and provided significant mood benefits.

A study from a few years ago also found that a single dose of psilocybin was capable of alleviating the trauma suffered by PTSD patients while a 2020 review of psychedelic research revealed that psychedelic treatment could reduce anxiety by up to 65%.

This therapeutic potential hasn’t been lost on investors, and startups such as Seelos Therapeutics Inc. (NASDAQ: SEEL) are seeing a lot of capital inflows and trading activity.

Seelos Therapeutics Inc. (SEEL), closed Monday's trading session at $0.7125, off by 2.5441%, on 708,820 volume. The average volume for the last 3 months is 9.319M and the stock's 52-week low/high is $0.4803/$1.52.

Fisker Inc. (FSR)

Schaeffer's, InvestorPlace, StocksEarning, MarketClub Analysis, MarketBeat, QualityStocks, Kiplinger Today, The Street, The Online Investor, Early Bird, Trades Of The Day, Daily Trade Alert, TradersPro, StreetInsider, wyatt research newsletter, TipRanks, Cabot Wealth, InvestorsUnderground, CNBC Breaking News and Money Wealth Matters reported earlier on Fisker Inc. (FSR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The globe’s first open experiment in “wireless charging” will take place later this year on a kilometer-long strip in Balingen, Germany. Its purpose is to demonstrate the viability of a technology that has long been seen as aspirational and innovative in the EV charging industry.

BMW is one of many automakers that already offers cars with pads that allow recharging while the vehicle is parked. However, the possibility of recharging batteries while operating a vehicle (dynamic charging) has extensive consequences for the sector.

There are significantly insufficient charging stations to serve the several automobiles anticipated on the roadways, automakers and industry advocacy organizations have warned. Additionally, these groups have voiced concern over a possible scarcity of battery components by, or soon after, the next ten years. Nevertheless, according to analysts, dynamic charging enables cars to hold lighter batteries, allowing for the more efficient use of scarce resources throughout a greater number of vehicles.

According to Andreas Wendt, the project’s goal is not just to make wireless charging available to the general public throughout Germany. Another important feature involves the creation and application of a technology that will help general transportation organizers determine where to construct the leading transportation system in a certain region.

If the dynamic charging is shown to be scalable and economically viable, it may provide a workaround for the shortage of static charge stations. However, the technology still needs to overcome several major obstacles before it is validated. To prevent the technology from duplicating itself across brands and models, parts must be compatible, allowing competing car brands to share a charging system. Furthermore, the cost of installing underneath pads for charging may be expensive. There is also the broader issue of coordinating energy networks, the larger auto sector and main road operators.

But according to Michael Hurwitz, implementing this technology for private vehicles is far more difficult; therefore, fleets or controlled fleets will be the first to employ it. Hurwitz asserts that this technology has the best opportunity of succeeding if it is woven into the system of creating and maintaining roadways, both for commercial and operational purposes.

However, this decade will see some advancements in technology. Given that there are not enough plug-in charge stations, IDTechEx forecasts that drivers of high-end vehicles will possess about 700,000 of wirelessly recharged cars by 2032.

Automakers have already started experimenting with the technology. Although Volvo Cars intends to test wireless charging on its XC40 electric vehicles, Stellantis Fiat owner says it has been a process since 2021 on its private fleet. This is a useful strategy to assess future alternatives for charging electric vehicles.

As wireless charging gains ground, it is possible that future models from various EV makers such as Fisker Inc. (NYSE: FSR) will invariably come with equipment to tap this charging option.

Fisker Inc. (FSR), closed Monday's trading session at $6.63, off by 1.3393%, on 9,385,157 volume. The average volume for the last 3 months is 2.572M and the stock's 52-week low/high is $6.40/$14.74.

The QualityStocks Company Corner

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused onmerging traditional therapeutics with psychedelic research, todayannounced that it has filed a provisional patent application forthe use of its central nervous system (“CNS”) homing peptides totreat Alzheimer’s disease and the onset of dementia. Alzheimer’shas proven to be a progressive neurodegenerative disorderassociated with the destruction of higher brain structures, such asthose involved in cognition and memory function. The disease leadsto declines and deficits in memory, learning, language and theability to perform intentional and purposeful movements and isaccompanied by concomitant behavioral, emotional, interpersonal,and social deterioration. “There is still an unmet need foreffective methods to prevent and treat Alzheimer’s disease,” saidEric Weisblum, chief executive officer of Silo Pharma. “Our hope isa targeted delivery of a therapeutic agent to cells that causedisease or are affected by a disease can improve the treatment ofAlzheimer’s and dementia.”

To view the full press release, visit https://ibn.fm/HmqDE

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Monday's trading session at $2.86, up 14.8594%, on 2,587,658 volume. The average volume for the last 3 months is 205,140 and the stock's 52-week low/high is $2.25/$12.445.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN) recently announced the launch of its latest innovative product: anew game-changing lidar called Vista(R)-X120 Plus. “Building onCepton’s existing Vista-X90 lidar – an already established,groundbreaking automotive-grade lidar expected to be deployed inthe company’s flagship ADAS lidar series production program – theVista-X120 Plus aspires to raise another bar in the lidar market.With a reported 500% increase in data rate, 30° wider field ofview, over 20% reduction in size, and 50% reduction in height, theVista-X120 Plus appears to be the epitome of everything thatmatters in lidar manufacturing: safety, autonomy, softwaredefinability, and electrification,” a recent article reads. “Drivento achieve safe and autonomous transportation for everyone, Ceptonhas been committed to bringing lidar beyond the luxury car market.The Vista-X120 Plus helps bolster Cepton’s vision of enabling safeand autonomous transportation through mass-market lidar adoption.With the embeddable design, extraordinarily compact size, anddistinctive features designed to deliver seamless power efficiencyand lower manufacturing cost in automotive volumes, it aspires tobe a game-changing lidar for everyday consumer vehicles. Cepton isconfident that the Vista-X120 Plus can offer top-end performance atlower power consumption and, as such, is ideally suited for ADASand automotive driving applications, including electric vehicles.”

To view the full article, visit https://ibn.fm/dwyI0

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Monday's trading session at $1.21, up 2.5424%, on 210,095 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $12.445/$.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

  • SideChannel, a company on a mission to make cybersecuritysimple and accessible to company of all sizes, believes that asecure network begins with segmentation, an approach madepossible by the offering of vCISOs, together with theapplication of RealCISO and Enclave technology
  • RealCISO allows SideChannel to perform an important initialsecurity audit to identify your organization’s current securityposture
  • Enclave simplifies microsegmentation - a network securitytactic that shrinks your organization's attack surface

SideChannel (OTCQB: SDCH) believes that all companies should be able to easily, andaffordably, understand and manage cyber risk. It also believes thata secure network begins with segmentation, the breaking down ofcomplex tasks into easy-to-understand steps, enhancing productivityand reducing risk. This approach is made possible by the offeringof SideChannel’s vCISOs, and the application of Enclave andRealCISO technology.

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.

 

Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.

Enclave

Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Monday's trading session at $0.109, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0675/$0.18.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

  • Miami-based REZYFi Inc., is a mortgage lender that originatestraditional loans but strategically is focused onnon-traditional markets such as the cannabis industry
  • The cannabis industry has enjoyed a boom in market interest butstill needs a reliable loan source for real estate mortgages
  • REZYFi’s strength as a commercial real estate lender is basedon its licensing in the majority of states, with more to come,and in its proprietary automated / machine-learning technology
  • Improving national economy trends have reduced pressure onmortgage rates in recent weeks, and many analysts expect thatmortgage rates will continue to decrease through the end of theyear, increasing the number of loan-seekers in the process

Specialized mortgage loan originator REZYFi provides a critical service to the cannabis industry, which hasexploded on the scene in recent years despite the hefty challengesinvolved in obtaining mortgage loans from federally insured banksreluctant to service an industry legalized only on a state-by-statelevel.

REZYFi, a growth mortgage origination and specialized financing companyin the United States, is at the forefront of cannabis and realestate. “REZYFi originates, structures and invests in firstmortgage loans and alternative structured financing secured bycommercial real estate properties. REZYFi’s target market includeslicensed and permitted cannabis companies, owners of real estatewho lease to cannabis companies, and companies and individualhomeowners seeking a variety of real estate-related first andadditional mortgage-based financing… REZYFi operates through twowholly owned subsidiaries and is positioned as one of the firstcannabis mortgage bankers in the United States, an area mosttraditional banks are hesitant to serve,” a recent article reads.“REZYFi is using a diversified approach to the real estate lendingsector to capitalize on growth in multiple verticals in the yearsto come. The company’s experience, network of independent brokers,and proprietary technology allow it to leverage the industry andoffer a wide range of real estate and financing options that werenot readily available.”

To view the full article, visit https://ibn.fm/lHMUL

Only a few weeks after facing Republican opposition and beingexcluded from the fiscal year-end expenditure bill, Senate Democrats are reconsidering cannabis bankinglegislation. Senator Charles Schumer, the majority leader in the Senate, metwith a small group of Senate Democrats on Feb. 1, 2023, to discusshow they would plot out the bill in the next Congress despite whatappears to be a likely stalemate with Republicans in control. Theproposed bill would enable banks to provide services tomarijuana-related businesses in states where it is permitted. Lastyear, Senators Cory Booker (N.J.) and Ron Wyden, who was unable toattend the most recent meeting due to a prior engagement, uncoveredan exhaustive cannabis reform package. However, to win the supportof the GOP, Schumer oversaw negotiations that resulted in an agreement called Safe Banking Plus. As lawmakers ponder how to get cannabis banking enacted,innovative solutions like those provided by alternative financierssuch as REZYFi Inc. will continue to be the lifeblood of entities looking to scaletheir operations or launch new products.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.

Operations

REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.


Recent News

chart

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels (NYSE American: UUUU) (TSX: EFR) today announced completion of its acquisition of 17 mineralconcessions between the towns of Prado and Caravelas in the stateof Bahia, Brazil, totaling 15,089.71 hectares (approximately 37,300acres or 58.3 square miles). According to the announcement, closingof the “Bahia Project” followed the Brazilian Government’s approvalof the transfers to Energy Fuels’ wholly owned Brazilian subsidiaryEnergy Fuels Brazil, Ltda. At the closing, Energy Fuels paid themineral owners the remaining $21.9 million cash. “Energy Fuels hasachieved yet another important milestone for our expanding rareearth business through our acquisition of the Bahia Project. Welook forward to further defining the heavy mineral sand resourcethrough our sonic drilling program and moving forward toward miningin the most prospective areas of the project,” said Mark S.Chalmers, president and CEO of Energy Fuels. “Using conservativedevelopment and market assumptions, we expect to receive monaziteconcentrates from the Bahia Project at a very low cost within thenext few years. By receiving monazite feeds from a variety ofsources, including mineral projects that we own, like the BahiaProject, and open market purchases, like from Chemours and others,we expect to be a low-cost U.S. producer of advanced REEmaterials.”

To view the full press release, visit https://ibn.fm/KBBVt

Uranium prices are poised to soar this year amid a resurgence in nuclear energy among major economies such asthe United States. Nuclear energy has been losing popularity amongdeveloped nations for quite a while now, with countries such asGermany and Spain planning to phase out a majority of their nuclear power plants by 2030. Furthermore, nations such as Australia, Denmark, Italy and Norway had no nuclear power plants or did not support nuclear energy asof 2016. However, the energy crunch of 2021 and 2022 has promptedmost developed nations to rethink their nuclear phase-out plans. Severe supply chain disruptions coupled with soaring energy prices have renewed many nations’ interest in nuclear energy for powergeneration. Some nations are working to extend the lives ofexisting nuclear-fired power plants while others are investing in new nuclear power plants.As of February 2023, there were around 60 new nuclear reactors under construction in 15 countries. The United States has actually invested billions of dollars into extending the life of nuclear power plants beyond theirpredetermined shutdown dates. Rule added that the uranium marketcould have a bullish outlook over the next decade, as nuclear energy may play a major role in ensuring equitable and affordable access to electricity forall. As that bullish market takes firm shape, domestic nuclearextractors such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are likely to see a huge uptick in investor interest.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Monday's trading session at $7.17, off by 3.1081%, on 1,463,931 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.69/$11.00.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

  • Amir Reichman, BiondVax CEO, represented the company at thisyear’s BIO CEO & Investor Conference held at the MarriottMarquis, New York, on February 6-8
  • His presentation focused on the company’s recent successfulpre-clinical in vivo results on its innovative inhaled COVID-19treatment
  • Additional results from the study were release in January 2023,indicating that, compared to the control group, hamsters thatreceived the drug one day after infection had negligibleSARS-CoV-2 vital titers in their lungs and experienced asignificantly milder and shorter illness
  • BiondVax’s management is optimistic that its self-administeredinhaled NanoAbs will be highly attractive to at-risk peoplewishing to proactively, effectively, conveniently, and safelyprotect themselves

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, andcommercializing innovative immunotherapeutic products mainly fortreating infectious and autoimmune diseases, took part in the 2023BIO CEO & Investor Conference held at the Marriott Marquis, NewYork. The conference, which took place from February 6-8, offered aplatform for stakeholders in the biotech industry, bringingtogether C-Suite leaders and the investor and banking communitiesfor an opportunity to shape the future investment landscape in thebiotechnology sector (https://ibn.fm/zLsni).

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Monday's trading session at $2.48, off by 0.792063%, on 8,806 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.37/$22.90.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

EverGen (TSX.V: EVGN) (OTCQX: EVGIF), a leading Canadian renewable energy company and Canada’srenewable natural gas (“RNG”) infrastructure platform, owns threeprojects in its home province of British Columbia and movedeastward in 2022, making large investments in projects in Albertaand Ontario. “Moving East, EverGen completed its acquisition of a67% interest in Alberta’s Grow the Energy Circle Ltd., GrowTEC forshort, which is currently in the first phase of a core RNGexpansion project designed to produce ~80,000 GJ/year of RNG. Thefacility will then move into the second phase of the project, whichis expected to produce a total of 140,000 GJ/year of RNG,” a recentarticle reads. “That will give EverGen 300,000 GJ of RNG annuallywithout consideration yet for Project Radius, a 50/50 partnershipbetween EverGen and Northeast Renewables LP. The Radius portfolioconsists of three late-stage, on-farm RNG projects in southernOntario. Collectively, the projects are expected to produceapproximately 1.7 million gigajoules per year of RNG from organicfeedstock, cementing EverGen and Ontario as North American leadersin RNG.”

To view the full article, visit https://ibn.fm/bjOJG

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Monday's trading session at $2.37, off by 1.25%, on 3,219 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.365/$4.00.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

A recent study published by the American Medical Association (AMA)found that patients with chronic pain who used medical cannabis for more than a month experienced a significant drop in the amount of opioids they wereprescribed. The study, conducted by researchers at the New York Department of Health incollaboration with City University of New York and the MarijuanaManagement Office, examined 8,165 patients registered in thestate’s medical cannabis program. The researchers used data fromthe state’s medical marijuana programs from 2017 to 2019 to trackhow patients’ opioid prescriptions changed over time. The dataincluded patients who had at least one opioid prescription and arecommendation for medical cannabis at the time they received theirfirst marijuana prescription. According to the findings, the numberof opioids consumed by pain patients who received marijuana formore than 30 days was cut in half. Consequently, those who receivedmarijuana for less than 30 days only experienced reductions of 4%to 14%. Furthermore, another AMA study revealed that two in six people with chronic pain report using marijuana as aform of treatment, and the majority of those people have done so in place of otherpainkillers such as opioids. With such study results, it isn’tsurprising that a number of enterprises such as India Globalization Capital Inc. (NYSE American: IGC) are looking to develop a range of THC-based treatments for variousindications, such as chronic pain.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Monday's trading session at $0.3986, off by 0.623286%, on 48,923 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$1.16.

Recent News

MetAlert Inc. (OTC: MLRT)

The QualityStocks Daily Newsletter would like to spotlight MetAlert Inc. (OTC: MLRT).

A recent study carried out by UTHealth Houston investigators hasrevealed that the presence of apathy in patients suffering from mild cognitive impairments may be aprecursor to Alzheimer’s disease. Alzheimer’s is a debilitatingmental disorder that usually causes memory loss, poor judgment,personality changes and a general decline in cognitive faculties. While it is estimated to affect more than 6 million Americans ofall ages, a majority of the people with Alzheimer’s are over the age of 75. Memory problems areusually the first clear sign of Alzheimer’s in a patient, but forthe most part, physicians cannot detect the condition beforesymptoms start to develop. This new study suggests the possibility of creating an early diagnosis tool thatcould detect Alzheimer’s before symptoms develop by analyzingapathy in people with mild cognitive impairments. Apathy is acommon symptom in people with cognitive impairment. It is usuallycharacterized by reduced or lack of interest in day-to-day activities.For patients with Alzheimer’s and other cognitive degenerativeconditions that have progressed, supportive devices such as thelocation monitoring devices made by MetAlert Inc. (OTC: MLRT) can ease the work of caregivers concerned about keeping tabs onwhere their loved one is at all times.

MetAlert Inc. (OTC: MLRT) is a pioneer in location sensitive health monitoring devices (estimated $47 billion industry in 2021) and wearable technology products (industry forecast to reach $174 billion by 2030).

With over 20 years of experience and an extensive patent portfolio (30+), MetAlert is a leader for consumers/patients afflicted with Alzheimer’s, dementia, and autism (ADA). This market represents approximately 2.9% of the world’s population (approximately 34 million people in 24 developed countries). Due to specific behaviors (problems with memory, adversity to wearing unknown items, etc.) of consumers/patients in this market segment, traditional products, such as an iPhone or Fitbit, are not a practical solution. This has created a significant market with very few competitors for MetAlert.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, and selling products and services in GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. The company offers a global end-to-end hardware, software, and connectivity solution, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products and enterprise applications.

Using its award-winning, patented GPS SmartSole® as a hub for collecting and transmitting data to the cloud in real-time, MetAlert is expanding its value proposition to consumers and increasing its revenue per user (RPU) while creating the largest database of health statistics for ADA consumers/patients. MetAlert generates revenue from product sales, recurring subscriptions, intellectual property (IP) licensing, and professional services. The company has international distributors servicing customers in over 35 countries and is an approved U.S. military government contractor. Its customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers.

The company is headquartered in Los Angeles, California, with a sales office in London, England, and distributors across the globe.

Products

  • GPS SmartSoles® HUB (launched Q4 2022) is a GPS/BLE-equipped insole that allows remote monitoring, data collection, and encrypted data transmission to the cloud.
    • Telehealth (available Q4 2022) allows access remotely to doctors and other health professionals on an as-needed basis. This service will also function as the prescribing doctor once Medicare reimbursement codes are established.
    • Concierge (available Q4 2022) provides 24/7/365 enhanced emergency response that coordinates with all relevant parties to quickly detect false alarms and escalate response as needed.
    • Bluetooth Enabled Devices (available Q1 2023) include third-party devices that collect vitals and other health data and connect with the GPS Smartsoles® HUB.
    • Artificial Intelligence (available Q1 2023) software will evaluate the Teradata of health information identifying trends and respond to preestablished alert thresholds.
  • Take-Along Tracker is a small GPS tracking device – less than three inches long – that works with 4G cellular service and will have the same “HUB” functionality as the GPS Smartsoles®. This versatile and affordable mini tracker boasts super long battery life, with up to 14 days of operation per charge.
  • RoomMate™ is a wall-mounted alert system that detects and alerts caregivers about patient behavior that could lead to falls and injuries. The system features 3D infrared and wall-mounted sensors, eliminating the need for any other physical installation or wearables. RoomMate™ offers patient privacy by design. Images are not stored, but all actions are logged. It’s a unique solution for looking after patients without intruding on their personal space.

Market Outlook

According to Grand View Research (Patient Monitoring Devices Market Size & Share Report, 2030), the global patient monitoring devices market size was valued at $47.0 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2030. The expansion of the industry can be attributed to the rise in demand for monitoring devices used to measure, distribute, record, and display a variety of biometric data, including blood pressure, temperature, and blood oxygen saturation level.

The growing number of chronic disorders, such as diabetes, stroke, and kidney disease, are driving the demand for patient monitoring devices. For instance, according to the World Health Organization (WHO), about 422 million people globally have diabetes. Likewise, the number of asthma and chronic obstructive pulmonary disease patients (COPD) is increasing rapidly.

According to the WHO, around 235 million people suffer from asthma. As a result, peak flow meters, which are used to gauge respiration rate, are increasingly used. The market for patient monitoring devices is driven by the simplicity with which it is handled, transported, and remotely accessible. Major market players are engaging in a variety of tactics to expand the industry, including partnerships, cooperation, innovation, launches, and mergers.

During the COVID-19 outbreak, social segregation and quarantining procedures were put into place worldwide. Many people avoided regular hospital visits as a result. Many people now need routine home temperature and oxygen level monitoring to maintain track of their health, thereby demanding monitoring devices at home.

Various government programs are supporting the pandemic outbreak. The FDA has granted Emergency Use Authorizations (EUAs) for a few wearables and patient monitoring devices to improve access to medicines, monitor patients more closely, and lessen the risk of SARS-CoV-2 exposure to medical professionals during the COVID-19 pandemic.

The growing popularity of wearable and remote patient monitoring devices is another factor fueling the market’s expansion. By fusing clinical symptomology with vital indicators, wearable technology helps in the diagnosis of many chronic diseases. Thus, there has been a dramatic rise in the usage of wearable technology to combat COVID-19.

The wearable medical device market is anticipated to reach $174.48 Billion by 2030, expanding at a 27.1% CAGR during the forecast period (2022-2030), according to Market Research Future.

MetAlert identifies the total addressable market for its wearable patient monitoring tech for those with Alzheimer’s, dementia, and autism at more than 34 million potential patients in North America, Europe, South Africa, and Asia.

Management Team

Patrick E. Bertagna is Founder, CEO and Chairman at MetAlert. He began his career in apparel sales in 1983 and was promoted to national sales manager within two years. In 1986, he founded his first company importing apparel from Europe and selling to U.S. retailers from JCPenney to Neiman Marcus. He has founded several technology and apparel companies, including MetAlert in 2002, which he took public in 2008. He attended Cal State University Northridge with a business major and a psychology minor.

Louis Rosenbaum is COO of MetAlert. He co-founded Global Trek Xploration and was an initial investor in MetAlert. He has successfully started companies in multiple industries, including apparel, environmental services, and the music industry, achieving annual revenues in the multi-millions of dollars. He previously was president of Elements, a women’s apparel company, and of Advanced Environmental Services.

Alex McKean is CFO at MetAlert. He is also the CFO of Encore Brands Inc., a position he has held since 2009. He has held positions as Controller and VP of Finance at 24:7 Film and InternetStudios.com, Director of FP&A/SVP at Franchise Mortgage Acceptance Company, Corporate Accounting Manager/Treasurer of Polygram Filmed Entertainment and Assistant Treasurer/Controller for State Street Bank. He holds an International MBA from Thunderbird School of Global Management and undergraduate degrees in business and political science from Trinity University.

MetAlert Inc. (OTC: MLRT), closed Monday's trading session at $0.15, off by 3.2258%, on 2,714 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.06/$1.00.

Recent News

CISO Global, Inc. (NASDAQ: CISO)

The QualityStocks Daily Newsletter would like to spotlight CISO Global, Inc. (NASDAQ: CISO).

Cerberus Cyber Sentinel Corporation (“Cerberus Sentinel” or the“Company”) (NASDAQ: CISO), an industry leader as a managedcybersecurity and compliance provider, based in Scottsdale, Ariz.,today announced that it has commenced an underwritten publicoffering of its common stock. In connection with the offering,Cerberus Sentinel intends to grant the underwriters a 30-day optionto purchase up to an additional 15% of the shares of its commonstock offered in the public offering. The offering is subject tomarket and other customary closing conditions, and there can be noassurance as to whether or when the offering may be completed, oras to the actual size or terms of the offering. Cantor Fitzgerald& Co. is acting as the sole book-running manager for theoffering. Cerberus Sentinel anticipates using the net proceeds fromthe proposed offering for general corporate purposes, which mayinclude working capital, capital expenditures, repayment andrefinancing of debt, research and development expenditures,acquisitions of additional companies or technologies, andinvestments.

CISO Global, Inc. (NASDAQ: CISO) is an industry leader in cybersecurity and compliance services. The company leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. Pulling disparate technologies, teams, and vendors together, CISO helps its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, CISO Global has worked to rapidly expand by acquiring world-class cybersecurity and compliance businesses with top-tier talent who utilize the latest technology to create innovative protection solutions.

The CISO Global workforce is comprised of cybersecurity experts spanning not only global geographies, but also specialties, industries, regulatory frameworks and focus areas. Its team includes audit and compliance specialists, certified forensics experts, ethical hackers, IEEE® certified biometric professionals, security engineers, around-the-clock analysts, and more – all backed by the most respected credentials in the industry. On an ongoing basis, the company works to identify cyber talent that is culturally aligned and that offers operating leverage through both existing customer revenue and relationships.

CISO Global has invested in enterprise solutions and executive talent to integrate its different organizations into an ecosystem that works together to provide complete cybersecurity through cross-pollination of solutions that begin at the network level and extend through technologies, people, policy, and practices. This ecosystem is intended to foster additional growth opportunities and drive overall recurring revenue. Once engaged, the company strives to become trusted advisors for customers’ cybersecurity and compliance demands by providing tailored security solutions based upon their organizational needs.

While cyber resilience requires cycles of continuous improvement, it is a journey that few in the current business and security climate seem to understand. With its deep bench of seasoned experts, CISO Global works to simplify that journey for its growing customer base, straightening out the curves and speeding up the process to resilience along the way.

Cybersecurity is a Culture, Not a Product

Integrating compliance and security, including principles of security by design, CISO Global helps its clients create an organization-wide culture of cybersecurity. Its offerings include audit and compliance, security operations center services, security engineering, virtual Chief Information Security Officer services, incident response, certified forensics, technical assessments and cybersecurity training.

In contrast to the majority of cybersecurity firms that specialize in a specific technology or service, CISO Global seeks to differentiate itself by remaining technology agnostic, focusing on accumulating highly sought-after subject matter experts. CISO Global believes that bringing together a world-class team of technological experts with multi-faceted proficiency in the critical aspects of cybersecurity is key to providing technology agnostic solutions to its clients in a business ecosystem that suffers from a chronic lack of highly skilled professionals.

CISO Global’s goal is to create a culture of security and to help quantify, define and capture a return on investment from information technology and cybersecurity spending. Its end-to-end, holistic process covers every aspect of clients’ cybersecurity and compliance requirements in an effort to promote greater efficiency and strengthen awareness about the integral role of internal team members in the cybersecurity culture of an organization.

As a result of this strategy, CISO Global customers receive an efficient engagement from a single partner that covers a wide range of their needs – addressing challenges more thoroughly and resolving problems more rapidly when compared to working with a host of vendors.

Market Outlook

According to an analysis by the firm Research and Markets, the global managed security services market was valued at $22.45 billion in 2020 and is projected to reach $77.01 billion by 2030, growing at a CAGR of 12.8% through the forecast period.

An expected increase in cybercrime, cost effectiveness of provided solutions and stringent mandatory government regulations aimed at protecting corporate data will drive the global managed security services market for the foreseeable future.

In addition, the documented and growing use of mobile devices in the workplace and the rise in captured and stored digital data serve to fuel market growth. Moreover, growing awareness about the critical nature of data security, the growing importance of e-business and demand for customized services is expected to offer ample opportunities for expansion of the market during the forecast period.

Management Team

David Jemmett is CEO and founder of CISO Global. He has more than 35 years of executive management and technology experience with telecommunications, managed services, and cybersecurity consulting services. He previously held positions as CEO of GenResults, a leading provider of security consulting services and technology solutions, and as CTO and founder at ClearData Networks, a HIPAA-compliant HealthDATA cloud hosting platform.

Dave Bennett is COO at CISO Global. Since 2015, he has served on the President’s STEM Advisory Board of Grand Canyon University. Before joining CISO Global, he served as Chief Product Officer at Experian Health and as Senior Vice President, Product for Gainwell Technologies. He has also held positions as Vice President and Worldwide Head of Build, Healthcare and Life Sciences at DXC Technology, and as EVP, Product and Strategy at Orion Health.

Ashley Devoto is President and Chief Information Security Officer at CISO Global. Over the past 17 years, Devoto has worked with the cybersecurity elite to design, build, and operate world-class cybersecurity programs for large, diverse organizations in both government and commercial enterprises. Prior to joining CISO, Devoto served as CISO for Booz Allen Hamilton, as business information security officer (BISO) at Bank of America, and as a cyberspace operations officer in the United States Air Force.

Deb Smith is CFO at CISO Global. Prior to assuming that position, she was the company’s EVP, Finance and Accounting. She has also served as SVP, Global Accounting at International Cruise and Excursions Inc., and as Chief Accounting Officer for BeyondTrust, an information security software company. She has also held the positions of Corporate Controller at Aspect Software and Assistant Controller at JDA Software.

CISO Global, Inc. (NASDAQ: CISO), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Monday's trading session at $1.81, off by 5.2356%, on 49,187 volume. The average volume for the last 3 months is 46,156 and the stock's 52-week low/high is $1.23/$35.50.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Monday's trading session at $3.12, off by 5.1672%, on 87,989 volume. The average volume for the last 3 months is 87,918 and the stock's 52-week low/high is $0.62/$9.795.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.